Behçet Disease Clinical Trial
Official title:
Relation Between Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .
The purpose of the study is to determine whether plasma levels of the soluble urokinase plasminogen activator(suPAR) can serve as a blood-based biomarker for diagnosis of Behçet's disease and its correlation with disease activity.
Behçet's disease (BD) is a chronic, systemic vasculitis disease that can be evident in many systems and characterized by recurrent attacks, oral and/or genital aphthous ulcers, skin lesions, and inflammatory ocular findings. It was first described in 1937 by the Turkish dermatologist Hulusi Behçet.[1-3] Although with an unclear pathogenesis, BD is considered a type of vasculitis triggered by immunological mechanisms. Increased levels of pro-inflammatory cytokines are reported in patients with BD. In the afflicted organs, a remarkable infiltration of neutrophils and lymphocytes can be seen.[4-6] Diagnosis of BD is mainly clinical, on the association of symptoms, but diagnosis/classification criteria may help. Various sets of criteria were created for BD diagnosis and the recent one is the international criteria for Behçet's disease (ICBD) that was created by 27 countries in 2006 and revised in2014.[7] There is no standard laboratory marker for the diagnosis and follow-up of BD. certain cytokines and increased serum levels of C-reactive protein (CRP) are considered as markers of disease activity.[8] Soluble urokinase plasminogen activator receptor (suPAR), a potential new biomarker, is a soluble form of the membrane-bound receptors expressed from and comprising mainly of various immune cells (monocytes, neutrophils, activated T lymphocytes, macrophages, endothelial cells, keratinocytes, smooth muscle cells and even tumor cells. [9] Numerous studies on various inflammatory diseases, cancer, tuberculosis, central nervous system infections, sepsis, liver fibrosis and inflammatory bowel disease have shown increased systemic levels of suPAR. In these diseases, suPAR systemic levels are shown to have a prognostic value in determining disease severity.[10] ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04528082 -
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
|
Phase 3 | |
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Terminated |
NCT04609397 -
A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
|
Phase 2 | |
Not yet recruiting |
NCT05128357 -
IMPACT_BD (IMProving AdherenCe to Treatment in Behçet's Disease)
|
||
Not yet recruiting |
NCT04126850 -
Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease
|
||
Recruiting |
NCT05879419 -
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
|
Phase 4 | |
Completed |
NCT03209219 -
Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis
|
Phase 3 | |
Completed |
NCT04386824 -
Erectile Dysfunction in Patients With Non Ocular Behçet's Disease
|
||
Completed |
NCT02648581 -
Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease
|
Phase 2 | |
Recruiting |
NCT06451575 -
Thrombophilia and Thrombosis in Behçet's Disease
|
||
Recruiting |
NCT04530461 -
Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases
|
||
Not yet recruiting |
NCT06386744 -
Dusquetide for the Treatment of Behcet's Disease
|
Phase 2 | |
Recruiting |
NCT04334031 -
Deployment o the Multidisciplinary Prospective Cohort Imminent
|
N/A | |
Not yet recruiting |
NCT05715294 -
The Effect of Music on Sleep Quality in Behçet's Patients
|
N/A | |
Active, not recruiting |
NCT06266247 -
How Sirtuin Levels Change During Behçet Disease
|
N/A | |
Recruiting |
NCT04959435 -
Understanding the Role of Oral Microbiota in Behçet's Disease (BEHCETBIOT)
|
||
Recruiting |
NCT03837236 -
Inactivity Behavior and Exercise Bariers in Patients With Behçet Disease
|
N/A | |
Recruiting |
NCT03803462 -
Behçet's Disease Overall Damage Index
|